Modalis Therapeutics Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	40	1
Revenue Growth (YoY)	-	-	-	3900.00%	-99.71%
Gross Profit	-	-	-	40	1
Selling, General & Admin	232	220	248	213	196
Research & Development	1,979	1,092	2,102	1,861	1,009
Other Operating Expenses	-	25	20	29	35
Operating Expenses	2,211	1,337	2,370	2,103	1,240
Operating Income	-2,211	-1,337	-2,370	-2,063	-1,239
Interest Expense	-9	-8	-15	-4	-1
Interest & Investment Income	3	-	-	-	-
Currency Exchange Gain (Loss)	10	64	39	76	12
Other Non Operating Income (Expenses)	58	-23	-6	-4	1
EBT Excluding Unusual Items	-2,149	-1,304	-2,352	-1,995	-1,227
Gain (Loss) on Sale of Assets	-	-	-	-	-2
Asset Writedown	-2	-	-38	-996	-
Other Unusual Items	-	-13	-	285	485
Pretax Income	-2,151	-1,317	-2,390	-2,706	-744
Income Tax Expense	1	-	1	-4	-6
Net Income	-2,152	-1,317	-2,391	-2,702	-738
Net Income to Common	-2,152	-1,317	-2,391	-2,702	-738
Shares Outstanding (Basic)	77	46	31	29	29
Shares Outstanding (Diluted)	77	46	31	29	29
Shares Change (YoY)	67.52%	48.96%	6.39%	1.23%	9.12%
EPS (Basic)	-27.85	-28.55	-77.21	-92.83	-25.67
EPS (Diluted)	-27.85	-28.55	-77.21	-92.83	-25.67
Free Cash Flow	-2,120	-1,432	-2,293	-2,092	-854
Free Cash Flow Per Share	-27.44	-31.05	-74.05	-71.87	-29.70
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-5157.50%	-123900.00%
Profit Margin	-	-	-	-6755.00%	-73800.00%
Free Cash Flow Margin	-	-	-	-5230.00%	-85400.00%
EBITDA	-	-1,336	-2,369	-1,940	-1,162
D&A For EBITDA	-	0.73	0.73	123	77
EBIT	-2,211	-1,337	-2,370	-2,063	-1,239

Source: S&P Global Market Intelligence. Standard template. Financial Sources.